Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

28.62 +0.27 (+0.95%)
Streaming Delayed Price Updated: 1:14 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗
 
Via Benzinga
News headline image
Dow Jumps 100 Points; US GDP Rises 2.4% In Q2 ↗
U.S. stocks traded higher this morning, following the release of major economic reports on Thursday. Following the market opening Thursday, the Dow traded up 0.28% to 35,620.79 while the NASDAQ rose... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Mersana Therapeutics ↗
 
Via Benzinga
News headline image
Mersana Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Cancer Drug Trials Put On Hold After Patients Died ↗
Recent reports from two drug companies that had been conducing separate clinical trials to evaluate cancer treatments reveal that the trials were halted due to the deaths of six participants, including... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023 ↗
 
Via Benzinga
News headline image
NVIDIA To Rally Over 17%? Here Are 10 Other Analyst Forecasts For Friday ↗
Raymond James boosted the price target for Jabil Inc. (NYSE: JBL) from $100 to $120. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares rose 5% to close at $104.64 on... 
Via Benzinga
News headline image
Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results ↗
U.S. stocks traded higher toward the end of trading, with Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.32% to 34,429.39 while the NASDAQ rose 1.27% to 13,799.28. The S&P 500,... 
Via Benzinga
News headline image
FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death ↗
 
Via Benzinga
Mersana Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Mersana's UpRi Shows Potential in Ovarian Cancer; Analyst Initiates Coverage with Buy Rating ↗
Guggenheim Partners has initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. 
Via Benzinga
News headline image
Dow Surges Over 300 Points; Kroger Profit Beats Views ↗
U.S. stocks traded higher midway through trading, with Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.98% to 34,313.85 while the NASDAQ rose 0.73% to 13,726.16. The S&P 500,... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗
 
Via Benzinga
News headline image
US Stocks Open Higher; Retail Sales Rise In May ↗
U.S. stocks traded higher this morning, with Dow Jones gaining around 180 points on Thursday. Following the market opening Thursday, the Dow traded up 0.53% to 34,159.59 while the NASDAQ rose 0.18% to... 
Via Benzinga
News headline image
Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser ↗
Markets gave back some ground after consideration of the Fed's latest interest rate decision. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Are Mersana Therapeutics Shares Nosediving Today ↗
The FDA has issued a partial clinical hold pausing new patient enrollment in Mersana Therapeutics Inc's (NASDAQ: MRSN) UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in  
Via Benzinga
News headline image
7 Stocks to Buy for 200% Returns This Year ↗
These high return stock investments all have the potential to triple in 2023 based on Wall Street expectations. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
US Stocks Edge Higher; AMD Shares Tank Despite Upbeat Results ↗
U.S. stocks traded up this morning, ahead of the Federal Reserve’s decision on an interest rate hike. Following the market opening Wednesday, the Dow traded up 0.05% to 33,700.93 while the NASDAQ rose... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗
 
Via Benzinga
News headline image
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics ↗
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗
 
Via Benzinga
News headline image
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
News headline image
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Recap: Mersana Therapeutics Q3 Earnings ↗
Mersana Therapeutics (NASDAQ:MRSN) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Mersana Therapeutics... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.